Covaxin Phase 3 trials results to be published in July: Bharat Biotech
New Delhi : Bharat Biotech will be applying for a full license for Covaxin once it will publish the results of Phase 3 trials in July, said the company on Friday.
Talking about the efficacy of the vaccine, the company claimed that it showed 78 per cent effectiveness overall and 100 per cent against hospitalisation, ANI reported today.
"It is critical to understand the phase 3 data will first be submitted to CDSCO," ANI reported Bharat Biotech as saying, referring to the Central Drugs Standard Control Organisation.
As notified earlier, the complete data of Phase 3 trials will be made public in July 2021.
The company also rubbished the reports which claimed that Covishield produced more antibodies than Covaxin.
"It's neither a peer-reviewed publication nor a statistically and scientifically designed study. The study design and conduct reflect an ad hoc analysis...further, the study was not...approved by CDSCO," Bharat Biotech said.
"Bharat Biotech is also doing phase 4 trials to check on the real-world effectiveness of the vaccines, and to ensure its vaccine met every rigorous scientific standard for safety, effectiveness, and manufacturing quality needed to support emergency use authorisation," ANI reported it as saying.